Prior to joining Novo Ventures, Dr. Reiss served as Global Head of Clinical Research and Development, Inflammation & Immunology at Celgene; Global Head of Clinical Development, Primary Care at Novartis; and Research Professor of Medicine at Vanderbilt University. Previous to that, he worked at Merck & Co. Inc, where he held positions of increasing responsibility in Clinical Development across multiple therapeutic areas, including Respiratory and Allergy, Bone and Muscle, Gastroenterology, Endocrine, and Urology. Dr. Reiss serves on the FDA Science Board and previously served on the FDA Pulmonary Advisory Committee.
Dr. Reiss received his MD degree from Vanderbilt University and completed his post-graduate training in Medicine at Columbia University (P&S) School of Medicine. He then completed a Pulmonary & Critical Care fellowship, as well as research training in cell biology and pharmacology, at the University of California, San Francisco. Dr. Reiss received his undergraduate degree and a Masters in Bioethics from the University of Pennsylvania.